Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings.
Demirci RA, Ghodsi A, Gulati R, Behnia S, Nelson PS, Cheng HH, Yezefski TA, Haffner MC, Hawley JE, Montgomery RB, Yu EY, Schweizer MT, Chen DL, Iravani A. Demirci RA, et al. Among authors: yezefski ta. J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167. Online ahead of print. J Nucl Med. 2024. PMID: 39542703
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study.
Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Raychaudhuri R, et al. JCO Precis Oncol. 2024 Apr;8:e2300634. doi: 10.1200/PO.23.00634. JCO Precis Oncol. 2024. PMID: 38662984
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH. Sokolova AO, et al. Among authors: yezefski ta. Prostate. 2021 Dec;81(16):1382-1389. doi: 10.1002/pros.24236. Epub 2021 Sep 13. Prostate. 2021. PMID: 34516663 Free PMC article.
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, Patel RA, De Sarkar N, Ha G, Dumpit R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, Nega K, Hammond J, Grivas P, Hsieh A, Montgomery B, Nelson PS, Yu EY. Schweizer MT, et al. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):194-200. doi: 10.1038/s41391-022-00636-0. Epub 2022 Dec 23. Prostate Cancer Prostatic Dis. 2023. PMID: 36564459 Free PMC article.
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B. Cheng HH, et al. JCO Precis Oncol. 2023 Jan;7:e2200104. doi: 10.1200/PO.22.00104. JCO Precis Oncol. 2023. PMID: 36623239 Free PMC article.
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.
Diamantopoulos LN, Holt SK, Khaki AR, Sekar RR, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Psutka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. Diamantopoulos LN, et al. Clin Genitourin Cancer. 2021 Apr;19(2):144-154. doi: 10.1016/j.clgc.2020.10.002. Epub 2020 Oct 14. Clin Genitourin Cancer. 2021. PMID: 33160889 Free PMC article.
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy.
Diamantopoulos LN, Sekar RR, Holt SK, Khaki AR, Miller NJ, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Psutka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. Diamantopoulos LN, et al. Urol Oncol. 2021 Aug;39(8):496.e1-496.e8. doi: 10.1016/j.urolonc.2021.01.009. Epub 2021 Feb 5. Urol Oncol. 2021. PMID: 33551249
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Graham LS, et al. Prostate. 2021 May;81(7):418-426. doi: 10.1002/pros.24118. Epub 2021 Mar 23. Prostate. 2021. PMID: 33755225 Free PMC article.
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.
Diamantopoulos LN, Khaki AR, Grivas P, Gore JL, Schade GR, Hsieh AC, Lee JK, Yezefski T, Yu EY, Schweizer MT, Cheng HH, Psutka SP, Lin DW, Tretiakova MS, Vakar-Lopez F, Montgomery RB, Wright JL. Diamantopoulos LN, et al. Bladder Cancer. 2020;6(1):71-81. doi: 10.3233/blc-190258. Epub 2020 Mar 28. Bladder Cancer. 2020. PMID: 34109262 Free PMC article.
19 results